Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Growth Hormone Research Society Perspective on the Development of Long-Acting Growth Hormone Preparations

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Calcium transport in male reproduction is possibly influenced by vitamin D and CaSR

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Accelerated loss of oogonia and impaired folliculogenesis in females with Turner syndrome start during early fetal development

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Thyroid function in COVID-19 and the association with cytokine levels and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cohort profile: The COPENHAGEN Minipuberty Study-A longitudinal prospective cohort of healthy full-term infants and their parents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jens Sandahl Christiansen
  • Philippe Backeljauw
  • Martin Bidlingmaier
  • Beverly Biller
  • Margaret Boguszewski
  • Felipe F Casanueva
  • Philippe Chanson
  • Pierre Chatelain
  • Catherine S Choong
  • David R Clemmons
  • Laurie Cohen
  • Pinchas Cohen
  • Jan Frystyk
  • Adda Grimberg
  • Yukihiro Hasegawa
  • Morey Haymond
  • Ken Ho
  • Andrew R Hoffman
  • Jeff Mp Holly
  • Reiko Horikawa
  • Charlotte Hoybye
  • Jens Otto L Jorgensen
  • Gudmundur Johannsson
  • Anders Juul
  • Laurence Katznelson
  • John J Kopchick
  • K-O Lee
  • Kuk Wha Lee
  • Xiao-Ping Luo
  • Shlomo Melmed
  • Bs Miller
  • Madhusmita Misra
  • Vera Popović
  • Ron G Rosenfeld
  • Judith Ross
  • Richard J Ross
  • Paul Saenger
  • Christian J Strasburger
  • Michael O Thorner
  • Haim Werner
  • Kevin Cj Yuen
Vis graf over relationer

OBJECTIVE: The Growth Hormone (GH) Research Society convened a workshop to address important issues regarding trial design, efficacy, and safety of long-acting GH preparations (LAGH).

PARTICIPANTS: A closed meeting of 55 international scientists with expertise in growth hormone, including pediatric and adult endocrinologists, basic scientists, regulatory scientists, and participants from the pharmaceutical industry.

EVIDENCE: Current literature was reviewed for gaps in knowledge. Expert opinion was utilized to suggest studies required to address potential safety and efficacy issues.

CONSENSUS PROCESS: Following plenary presentations summarizing the literature, breakout groups discussed questions framed by the planning committee. Attendees re-convened after each breakout session to share group reports. A writing team compiled the breakout session reports into a draft document that was discussed and revised in an open forum on the concluding day. This was edited further and then circulated to attendees from academic institutions for review after the meeting. Participants from pharmaceutical companies did not participate in the planning, writing, or in the discussions and text revision on the final day of the workshop. Scientists from industry and regulatory agencies reviewed the manuscript to identify any factual errors.

CONCLUSIONS: LAGH compounds may represent an advance over daily GH injections because of increased convenience and differing phamacodynamic properties, providing the potential for improved adherence and outcomes. Better methods to assess adherence must be developed and validated. Long-term surveillance registries that include assessment of efficacy, cost-benefit, disease burden, quality of life, and safety are essential for understanding the impact of sustained exposure to LAGH preparations.

OriginalsprogEngelsk
TidsskriftEuropean journal of endocrinology / European Federation of Endocrine Societies
Vol/bind174
Udgave nummer6
Sider (fra-til)C1-8
Antal sider9
ISSN0804-4643
DOI
StatusUdgivet - 23 mar. 2016

ID: 46346499